Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Aug 19;8(8):e66848.
doi: 10.1371/journal.pone.0066848. eCollection 2013.

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer

Otto Metzger-Filho  1 , Aurélie Catteau, Stefan Michiels, Marc Buyse, Michail Ignatiadis, Kamal S Saini, Evandro de Azambuja, Virginie Fasolo, Sihem Naji, Jean Luc Canon, Paul Delrée, Michel Coibion, Pino Cusumano, Veronique Jossa, Jean Pierre Kains, Denis Larsimont, Vincent Richard, Daniel Faverly, Nathalie Cornez, Peter Vuylsteke, Brigitte Vanderschueren, Hélène Peyro-Saint-Paul, Martine Piccart, Christos Sotiriou
Affiliations
Clinical Trial

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer

Otto Metzger-Filho et al. PLoS One. .

Abstract

Purpose: Genomic Grade Index (GGI) is a 97-gene signature that improves histologic grade (HG) classification in invasive breast carcinoma. In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its impact on treatment recommendations.

Methods: Patients with pT1pT2 or operable pT3, N0-3 invasive breast carcinoma were recruited from 8 centers in Belgium. Fresh surgical samples were sent at room temperature in the MapQuant Dx™ PathKit for centralized genomic analysis. Genomic profiles were determined using Affymetrix U133 Plus 2.0 and GGI calculated using the MapQuant Dx® protocol, which defines tumors as low or high Genomic Grade (GG-1 and GG-3 respectively).

Results: 180 pts were recruited and 155 were eligible. The MapQuant test was performed in 142 cases and GGI was obtained in 78% of cases (n=111). Reasons for failures were 15 samples with <30% of invasive tumor cells (11%), 15 with insufficient RNA quality (10%), and 1 failed hybridization (<1%). For tumors with an available representative sample (≥ 30% inv. tumor cells) (n=127), the success rate was 87.5%. GGI reclassified 69% of the 54 HG2 tumors as GG-1 (54%) or GG-3 (46%). Changes in treatment recommendations occurred mainly in the subset of HG2 tumors reclassified into GG-3, with increased use of chemotherapy in this subset.

Conclusion: The use of GGI is feasible in routine clinical practice and impacts treatment decisions in early-stage breast cancer.

Trial registration: ClinicalTrials.gov NCT01916837, http://clinicaltrials.gov/ct2/show/NCT01916837.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have the following interests. Ipsogen SA provided financial support for the conduct of this study and is the employer of Aurélie Catteau, Virginie Fasolo, Sihem Naji and Hélčne Peyro-Saint-Paul. Drs. Sotiriou and Piccart are co-inventors of patent and patent applications on the CGI owned by Universite Libre de Bruxelles and licensed to Ipsogen SA. Virginie Fasolo is co-inventor of patent applications jointly owned by Universite Libre de Bruxelles and Ipsoegn SA and licensed to Ipsogen SA. The name of the Patent is "METHODS FOR THE DIAGNOSIS, THE DETERMINATION OF THE GRADE OF A SOLID TUMOR AND THE PROGNOSIS OF A SUBJECT SUFFERING FROM CANCER". There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Figures

Figure 1
Figure 1. Flow diagram of enrolled patients.
Abbreviations: inv, invasive; N, nodal status.
Figure 2
Figure 2. Impact of GGI reclassification on treatment decisions in ER+ and HER2-negative and HG2 early-stage breast cancer.
Abbreviations: CP, treatment decision based on clinico-pathologic characteristics; CHT, chemotherapy plus hormonotherapy; HT, hormonotherapy; final, final treatment decision based on GG results and discussion with patient.
See this image and copyright information in PMC

References

    1. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800. doi:10.1056/NEJMra0801289. PubMed: 19228622. - DOI - PubMed
    1. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009. doi:10.1056/NEJMoa021967. PubMed: 12490681. - DOI - PubMed
    1. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272. doi:10.1093/jnci/djj052. PubMed: 16478745. - DOI - PubMed
    1. Paik S, Shak S, Tang G, Kim C, Baker J et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826. doi:10.1056/NEJMoa041588. PubMed: 15591335. - DOI - PubMed
    1. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11: 55-65. doi:10.1016/S1470-2045(09)70314-6. PubMed: 20005174. - DOI - PMC - PubMed

MeSH terms

Associated data